These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

777 related items for PubMed ID: 9135695

  • 1. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 2. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [Abstract] [Full Text] [Related]

  • 3. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F.
    Urol Int; 2004 Mar; 72(1):62-5. PubMed ID: 14730168
    [Abstract] [Full Text] [Related]

  • 4. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y, Sakai H, Hayashi T, Kanetake H.
    Prostate; 2003 Feb 01; 54(2):125-32. PubMed ID: 12497585
    [Abstract] [Full Text] [Related]

  • 5. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb 01; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 6. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M, Wachter J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S.
    Eur Urol; 2005 Jul 01; 48(1):34-9. PubMed ID: 15967249
    [Abstract] [Full Text] [Related]

  • 7. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
    Trapeznikova MF, Shibaeva AN, Ianshin AA, Urenkov SB, Mironova OS, Kazantseva IA, Kushlinskiĭ NE.
    Urologiia; 2004 Jul 01; (1):17-21. PubMed ID: 15022438
    [Abstract] [Full Text] [Related]

  • 8. [Analysis of serum insulin-like growth factor-1 and insulin-like growth factor-binding protein-3 in benign prostatic hyperplasia].
    Yu JP, Wu XM, Chen JG, Liu WM, Yang QX.
    Zhonghua Nan Ke Xue; 2003 Aug 01; 9(5):341-3. PubMed ID: 14513639
    [Abstract] [Full Text] [Related]

  • 9. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F, Kwiatkowski MK, Piironen T, Pettersson K, Lümmen G, Wernli M, Wiefelspütz J, Graber SF, Goepel M, Huber A, Tscholl R.
    Cancer; 1998 Dec 15; 83(12):2540-7. PubMed ID: 9874461
    [Abstract] [Full Text] [Related]

  • 10. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA.
    Scorilas A, Plebani M, Mazza S, Basso D, Soosaipillai AR, Katsaros N, Pagano F, Diamandis EP.
    Prostate; 2003 Feb 15; 54(3):220-9. PubMed ID: 12518327
    [Abstract] [Full Text] [Related]

  • 11. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J, Millet C, Levillain P, Doré B, Bégon F, Aubert J.
    Chirurgie; 1997 Feb 15; 122(8-9):478-82. PubMed ID: 9616891
    [Abstract] [Full Text] [Related]

  • 12. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug 15; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

  • 13. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J, Diamandi A, Mistry J, Scorilas A.
    J Clin Endocrinol Metab; 2001 Feb 15; 86(2):694-9. PubMed ID: 11158033
    [Abstract] [Full Text] [Related]

  • 14. Total and free PSA: a methodical and clinical evaluation of five assays.
    Reiter W, Stieber P, Schmeller N, Nagel D, Hofmann K, Fateh-Moghadam A.
    Anticancer Res; 1997 Feb 15; 17(6D):4759-65. PubMed ID: 9494603
    [Abstract] [Full Text] [Related]

  • 15. [A comparison between prostate-acid-phosphatase and prostate-specific antigen in the diagnosis of prostatic carcinoma].
    Bentvelsen FM, Bogdanowicz JF, Oosterom R, Schröder FH.
    Ned Tijdschr Geneeskd; 1990 Aug 18; 134(33):1596-600. PubMed ID: 1697651
    [Abstract] [Full Text] [Related]

  • 16. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia.
    Stephan C, Lein M, Jung K, Schnorr D, Loening SA.
    Cancer; 1997 Jan 01; 79(1):104-9. PubMed ID: 8988733
    [Abstract] [Full Text] [Related]

  • 17. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
    Muecke R, Klotz T, Giedl J, Buentzel J, Kundt G, Kisters K, Prott FJ, Micke O.
    Acta Oncol; 2009 Jan 01; 48(3):452-6. PubMed ID: 18855158
    [Abstract] [Full Text] [Related]

  • 18. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
    Kehinde EO, Akanji AO, Mojiminiyi OA, Bashir AA, Daar AS, Varghese R.
    Prostate Cancer Prostatic Dis; 2005 Jan 01; 8(1):84-90. PubMed ID: 15775992
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF, Bentvelsen FM, Oosterom R, Schroeder FH.
    Scand J Urol Nephrol Suppl; 1991 Jan 01; 138():97-103. PubMed ID: 1723815
    [Abstract] [Full Text] [Related]

  • 20. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
    Paus E, Nilsson O, Børmer OP, Fosså SD, Otnes B, Skovlund E.
    J Urol; 1998 May 01; 159(5):1599-605. PubMed ID: 9554362
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.